

Ann S Lacasce

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1124437/publications.pdf>

Version: 2024-02-01

104
papers

4,143
citations

156536

32
h-index

134545

62
g-index

105
all docs

105
docs citations

105
times ranked

5713
citing authors

#	ARTICLE	IF	CITATIONS
1	Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 1271-1281.	0.6	18
2	Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2023, 7, 2309-2316.	2.5	6
3	Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. <i>Blood</i> , 2022, 139, 1147-1159.	0.6	17
4	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	0.6	7
5	Exploring the Feasibility of a Mindfulness-Music Therapy Intervention to Improve Anxiety and Stress in Adolescents and Young Adults with Cancer. <i>Journal of Pain and Symptom Management</i> , 2022, 63, e357-e363.	0.6	9
6	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
7	The treatment of Burkitt lymphoma in adults. <i>Blood</i> , 2021, 137, 743-750.	0.6	45
8	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. <i>Blood</i> , 2021, 137, 1353-1364.	0.6	31
9	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. <i>Hematological Oncology</i> , 2021, 39, 185-195.	0.8	12
10	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	2.5	28
11	Late toxicities in non-Hodgkin lymphoma: extended follow-up matters. <i>Lancet Haematology</i> , 2021, 8, e242-e243.	2.2	0
12	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. <i>Blood</i> , 2021, 138, 427-438.	0.6	109
13	Integrating Novel Agents into the Treatment of Classic Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S166-S167.	0.2	0
14	Dana-Farber Cancer Institute/Mass General Brigham Fellowship Response to the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2021, 17, 541-545.	1.4	3
15	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , 2021, 22, 1391-1402.	5.1	53
16	Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 640-640.	0.6	4
17	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	2.5	40
18	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 122-126.	2.5	46

#	ARTICLE	IF	CITATIONS
19	Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 189, e86-e90.	1.2	25
20	Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 20-21.	0.6	16
21	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	0.6	4
22	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , 2020, 136, 37-38.	0.6	1
23	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1238-1246.	0.6	86
24	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e419-e428.	2.2	60
25	Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 606-613.	0.6	41
26	Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease. <i>Hematological Oncology</i> , 2019, 37, 87-91.	0.8	32
27	Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition. <i>JAAD Case Reports</i> , 2019, 5, 401-405.	0.4	10
28	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.	0.6	129
29	Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders. <i>Frontiers in Oncology</i> , 2019, 9, 109.	1.3	63
30	Novel agents and immune invasion in Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 243-248.	0.9	3
31	Suicide in European Hodgkin Lymphoma Patients. <i>HemaSphere</i> , 2019, 3, e183.	1.2	3
32	Current considerations in AYA Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 72-81.	1.2	20
33	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1312-1315.	0.6	3
34	Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 32-32.	0.6	28
35	Evidence-Based Minireview: What is the optimal timing of anti-PD-1 antibodies in relapsed classical Hodgkin lymphoma?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 249-251.	0.9	0
36	Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, e338-e342.	0.3	9

#	ARTICLE	IF	CITATIONS
37	Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 132, 40-48.	0.6	199
38	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 1183-1194.	0.6	276
39	Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26707.	0.8	4
40	Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. <i>Blood Advances</i> , 2018, 2, 1334-1343.	2.5	23
41	Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and Tj ETQq1 1 0.784314 rgBT /Overlo prospective, multicentre, single-arm phase 2 study. <i>Lancet Haematology</i> , the, 2018, 5, e609-e617.	2.2	152
42	Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. <i>PLoS ONE</i> , 2018, 13, e0199708.	1.1	4
43	A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1654-1654.	0.6	2
44	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	0.8	339
45	Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. <i>Journal of Infectious Diseases</i> , 2017, 216, 254-262.	1.9	41
46	Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted <sc>EPOCH</sc>. <i>British Journal of Haematology</i> , 2017, 179, 739-747.	1.2	101
47	Case 25-2017. <i>New England Journal of Medicine</i> , 2017, 377, 677-688.	13.9	0
48	How to Approach a Patient With Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 710-715.	0.2	2
49	Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes. <i>Blood Advances</i> , 2017, 1, 1945-1958.	2.5	25
50	The Evolution of Immunotherapy in Lymphoma. , 2017, 14, .		0
51	Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 649-649.	0.6	7
52	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1067-1079.	2.3	107
53	High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1274-1281.	2.3	7
54	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	7.7	227

#	ARTICLE	IF	CITATIONS
55	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	0.8	239
56	Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. <i>Haematologica</i> , 2016, 101, 1237-1243.	1.7	42
57	A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	1.2	51
58	Hospice Use Among Patients With Lymphoma: Impact of Disease Aggressiveness and Curability. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv280.	3.0	47
59	Nivolumab (Anti-PD1) Therapy for Relapsed/ Refractory Primary Central Nervous System Lymphoma and Primary Testicular Lymphoma. <i>Blood</i> , 2016, 128, 930-930.	0.6	2
60	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.	0.6	3
61	Novel Targets in Primary Central Nervous System Lymphoma. , 2016, 13, .		0
62	Understanding Immune Escape in Classical Hodgkin Lymphoma. , 2016, 13, .		0
63	Characterizing Pediatric-Type Nodal Follicular Lymphoma. , 2016, 13, .		0
64	Targeting PD-1 Classical Hodgkin Lymphoma. , 2016, 13, .		0
65	Using Interim PET to Direct Therapy for Early Hodgkin Lymphoma: Results from the Trials. , 2016, 13, .		0
66	BCL-2 Is an Effective Target in Chronic Lymphocytic Leukemia. , 2016, 13, .		0
67	Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. <i>PET Clinics</i> , 2015, 10, 207-225.	1.5	11
68	The epidemiology of herpes zoster and its complications in Medicare cancer patients. <i>BMC Infectious Diseases</i> , 2015, 15, 106.	1.3	37
69	A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL. <i>Blood</i> , 2015, 126, 4159-4159.	0.6	1
70	Targeted Therapy in Lymphoproliferative Disorders (Excluding CAR T Cells). , 2015, 12, .		0
71	Circulating Tumor Specific DNA: A Promising Biomarker in Diffuse Large B-cell Lymphoma. , 2015, 12, .		0
72	PD-1 Inhibition and Hodgkin Lymphoma: A Perfect Therapeutic Match. , 2015, 12, .		0

#	ARTICLE	IF	CITATIONS
73	M7FLIPI: A Follicular Lymphoma Prognostic Model for the 21st Century. , 2015, 12, .		0
74	CAR T Cells in Refractory Diffuse Large B-cell Lymphoma. , 2015, 12, .		0
75	Navigating Future Challenges in Lymphoma: A Map for the Road Ahead. , 2015, 12, .		0
76	Comparison of referring and final pathology for patients with Tâ€cell lymphoma in the National Comprehensive Cancer Network. Cancer, 2014, 120, 1993-1999.	2.0	36
77	How I treat Burkitt lymphoma in adults. Blood, 2014, 124, 2913-2920.	0.6	76
78	Latency No Longer a Haven for Epstein-Barr Virus. , 2014, 11, .		0
79	Targeting Bromodomain Proteins in DLBCL. , 2014, 11, .		0
80	Unlocking the Mysteries of AITL. , 2014, 11, .		0
81	The Role of Brentuximab Vedotin in Previously Untreated Patients with CD30-Positive T-Cell Lymphoma. , 2014, 11, .		0
82	NF-ÎB is Key in Mantle Cell Lymphoma. , 2014, 11, .		0
83	Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1â€2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leukemia and Lymphoma, 2013, 54, 2155-2162.	0.6	12
84	Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood, 2012, 119, 2093-2099.	0.6	88
85	Optimal, Upfront Management of Mantle Cell Lymphoma. , 2012, 9, .		0
86	An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.. Blood, 2012, 120, 2656-2656.	0.6	0
87	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. Blood, 2012, 120, 1980-1980.	0.6	0
88	Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood, 2011, 117, 5314-5320.	0.6	56
89	Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 1635-1635.	0.6	3
90	Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,. Blood, 2011, 118, 3716-3716.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1611-1615.	0.8	51
92	Reply to J. Mehta. <i>Journal of Clinical Oncology</i> , 2009, 27, e139-e140.	0.8	0
93	Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>Oncologist</i> , 2009, 14, 739-751.	1.9	62
94	R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project.. <i>Blood</i> , 2009, 114, 403-403.	0.6	8
95	Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database.. <i>Blood</i> , 2009, 114, 1387-1387.	0.6	15
96	Antibody and Immunomodulatory Agents in the Treatment of Indolent Non-Hodgkin's Lymphoma. <i>Seminars in Hematology</i> , 2008, 45, 85-89.	1.8	6
97	Enzastaurin. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 939-944.	1.9	47
98	Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network. <i>Journal of Clinical Oncology</i> , 2008, 26, 5107-5112.	0.8	75
99	High False Positive Rate with the Use of CT and FDG-PET in Post-Remission Surveillance for Hodgkin Lymphoma.. <i>Blood</i> , 2007, 110, 2327-2327.	0.6	2
100	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4496-4496.	0.6	2
101	Non-Myeloablative Allogeneic Transplantation for Hodgkin's and Non-Hodgkin's Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. <i>Blood</i> , 2007, 110, 3041-3041.	0.6	0
102	Potential Impact of Pathologic Review on Therapy in Non-Hodgkin's Lymphoma (NHL): Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project.. <i>Blood</i> , 2005, 106, 2816-2816.	0.6	1
103	Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3128-3135.	0.8	180
104	Putting the Heme Back in Heme-Onc: an Evaluation of the Redesigned Hematology Track within the Dana Farber/Mass General Brigham Hematology-Oncology Fellowship. <i>Journal of Cancer Education</i> , 0, , .	0.6	1